Study Posting (4519) -- Trial #122425, Kidney Transplantation, Toronto, ON, Canada

Click here to sign up to receive emails about new trial listings.

Trial Information

Summary: A Study of the Effect of CellCept (Mycophenolate Mofetil) on Renal Function After Withdrawal of Cyclosporine in Kidney Transplant Patients

Status: Completed

Protocol Number: M55012

Sponsor: F Hoffman-La Roche Ltd

Company Division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of CellCept on renal function after cyclosporine withdrawal in kidney transplant patients with deteriorating renal function

Brief Summary: This study will assess whether CellCept improves renal function following the withdrawal of cyclosporine in kidney transplant patients with deteriorating renal function. Following the core, treatment phase, a long-term observational follow-up phase will assess whether a treatment effect is maintained over time. The anticipated time on study treatment is >2 years, and the target sample size is <100 individuals. Target sample size is 79.

Study Phase: IV

Study Design / Study Details:

Purpose: Treatment
Allocation: Randomized
Masking: Open Label
Control: Active
Assignment: Parallel
Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Kidney Transplantation

Intervention Type: Drug

Intervention Name: mycophenolate mofetil[CellCept]

Primary Outcome: 1. Efficacy: Change in serum creatinine after withdrawal of cyclosporine

Key Secondary Outcomes: 1. Safety: Adverse events, opportunistic infections, malignancies

Inclusion Criteria:

adult male or female patients 18-65 years of age;
renal transplant >=15 months previously;
baseline biopsy and serum creatinine levels indicating deterioration of renal function within last 12 months;
patients receiving a cyclosporine-based immunosuppressant regime;
for follow-up phase: patients who completed the treatment phase of the study.

Exclusion Criteria:

current CellCept therapy, with cyclosporine or Prograf;
biopsy-proven acute rejection within 3 months 3 months prior to study entry;
female patients who are pregnant, breast-feeding or of childbearing potential, not willing to use reliable contraception during, or for 6 weeks following, conclusion of CellCept therapy;
patients simultaneously participating in another study, or who have participated in another study within 30 days of entry into the study;
for follow-up phase: patients who did not complete, or who switched therapy during, the treatment phase of the study.

Gender: Males or Females

Age Limits: Min: 18 Years Max: 65 Years

Accepts Healthy Volunteers: No

Trial Registration Date: 05/23/2005

Date Last Updated: 09/19/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Toronto, ON, Canada, M5G 2M9
Telephone: 973-235-5000 or 800-526-6367

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 2:47:18 PM

Back to Centerwatch Trial Listing by Location

Additional resources
in this illness area

Patient Resources: [ Trial Listing ] [ Notification Services ] [ Drug Directories ]
[ About Clinical Research ] [ Patient Resources ] [ Patient Bookstore ]
Professional Resources: [ Research Center Profiles ] [ Industry Provider Profiles ] [ Jobs in Clinical Research ]
[ Industry News ] [ Professional Resources ] [ Professional Bookstore ]
General: [ Search ] [ Site Map ] [ Your Privacy ] [ CW World ] [ Home ]